

# **OPIOID USE AND ABUSE IN THE OLDER ADULT POPULATION**

Linda Sobeski, PharmD, BCPS

Clinical Assistant Professor, UNMC COP

September 11, 2020

# OBJECTIVES

Characterize opioid use and abuse in the older adult population

Describe the risk factors related to opioid use in older adults

Explore strategies for the safe and rational use of opioid in older adults

## EPIDEMIOLOGY OF OPIOID USE IN ELDERLY



6-9% of community-dwelling older adults use opioids chronically



9% of clinic visits for older adults involve prescription of an opioid



Women (8.6%) and individuals with arthritis and depression are more likely to use opioids



Up to 70% of NH residents receive regularly scheduled opioids

Naples, et al. Clin Geriatr Med 2016;32:725-35.

Steinman, et al. Pain Med 2015;16:319-27.

Lapane et al. J Pain Symptom Manage 2013;45:33-42.

Tilly, et al. OUD Issue Brief, Administration for Community Living, 2017.



**AGE-RELATED RISKS OF  
OPIOID USE**

## CHANGES IN OPIOID METABOLISM WITH AGING



Decrease in first-pass metabolism of may increase oral bioavailability (F)  
e.g. morphine



Decrease in phase I metabolism may decrease systemic clearance and increase elimination half-life ( $t_{1/2}$ )  
e.g. oxycodone, ?buprenorphine



Effects on fentanyl unclear  
Levorphanol, methadone not studied


## PHARMACODYNAMIC CHANGES WITH AGING



Increased level and duration of pain relief with opioids




Dose-response relationship between exposure and risk of adverse drug effects



Coadministration with other CNS agents increases risk

# CHANGES IN RENAL ELIMINATION OF OPIOIDS WITH AGING




Renal function is decreased with age,  
independent of renal disease



Accumulation of renally-eliminated active  
metabolites may may lead to toxicity

e.g. oxycodone, hydromorphone, codeine, meperidine,  
tramadol

# RISKS OF OPIOID USE IN OLDER ADULTS



- Increased risk of fractures
- Established link between opioids and cognitive decline
- Increased risk of delirium
- Increased risk of hospitalization and ER visits
- Risk of abuse and misuse
- Other ADEs in older adults:
  - Motor vehicle accidents
  - CV events
  - Pneumonia
  - Death

Takkouche, et al. *Drug Saf* 2007;30:171-84.

Puustinen, et al. *BMC Geriatr* 2011;11:70.

Clegg, et al. *Age Aging* 2011;40:23-9.

Tilly, et al. *OAD Issue Brief, Administration for Community Living*, 2017.

# ABUSE & MISUSE OF OPIOIDS AMONG ELDERLY




Rates of opioid abuse lower in elderly population, but increasing

2.2% of adults 65+ report non-medical use of prescription opioids in past 12 months



Rates of inadvertent opioid misuse are higher in older adults



Rates of serious medical outcomes are higher in older adults

West, et al. Drug and Alcohol Dep 2015;149:117-21.

Reib, et al. Canadian Geriatr J 2020;23(1):123-134.

Tilley, et al. OUD Issue Brief, Administration for Community Living, 2017.

National Epidemiologic Survey on Alcohol and Related Conditions II (2012-2013):

## Tools for OUD Screening & Assessment

WHO Assist  
Tool (Part A)  
Clinician (8Q)

NIDA-Modified  
(NM) Assist  
Clinician (1+8Q)

Opioid Risk  
Tool  
Patient (10Q)

SOAPP  
Clinician (14Q)

COMM  
Patient (17Q)

PDMP

[https://www.who.int/substance\\_abuse/activities/assist\\_v3\\_english.pdf?ua=1](https://www.who.int/substance_abuse/activities/assist_v3_english.pdf?ua=1)

<https://www.drugabuse.gov/nidamed-medical-health-professionals/screening-tools-resources/chart-screening-tools>

Webster et al. Pain Med 2005;6(6):432.


<https://www.nhms.org/sites/default/files/Pdfs/SOAPP-14.pdf>

[http://nationalpaincentre.mcmaster.ca/documents/comm\\_sample\\_watermarked.pdf](http://nationalpaincentre.mcmaster.ca/documents/comm_sample_watermarked.pdf)

The background of the image is a soft-focus photograph of several white, oval-shaped pills scattered on a white paper napkin with a subtle grid pattern. The lighting is bright and even, creating a clean, clinical aesthetic. The pills are the primary subject, though they are out of focus to emphasize the text overlay.

# **OPIOID RISK MITIGATION**

# PRINCIPLES FOR CHRONIC PAIN MANAGEMENT




Use multi-modal, patient-centered, stepped approach



Incorporate non-pharmacologic and non-traditional approaches

e.g. CBT, PT, rehab, weight loss, exercise, meditation, massage, patient education, biofeedback

# EFFICACY OF OPIOIDS FOR CNCP



- Limited to short-term studies
- Functional and QOL outcomes often not reported
- Pooled data = small to modest improvement in pain intensity and physical function compared to placebo
- No rigorous long-term trials (>1yr) comparing opioids to non-opioid analgesics
- Concern that benefit may not outweigh risk

Papaleontiou, et al. J Am Geriatr Soc 2010;58:1358-69.  
Chou, et al. Ann Intern Med 2015;162:276.  
Ericksen, et al. Pain 2006;125:172-9.  
Naliboff, et al. J Am Pain Soc 2011; 12(2):288-96.

## ALTERNATIVES TO OPIOIDS FOR CNCP



APAP is first-line for OA and LBP  
Need 3-4g/d on routine schedule



PO NSAIDS (with caution) in carefully  
selected patients



Topicals: NSAIDs, lidocaine, capsaicin,  
menthol/methylsalicylate  
INJ: steroids, hyaluronic acid (OA)



Neuropathic pain: SNRIs, SSRIs, gabapentin,  
pregabalin, TCAs (with caution)

# PRINCIPLES OF OPIOID USE



- Use as adjunct to non-pharmacologic modalities and non-opioid analgesics for CNCP
- Limit acute use to  $\leq 7$  days
- Continue non-opioid analgesics to facilitate “opioid-sparing” dosing
- Consider tramadol, oxycodone, morphine
- Initiate with lower doses and titrate more slowly
- Consider tapering and decreased use of opioids
- Monitor for OUD
- Offer treatment, when indicated


## KEY POINTS



Elderly often use prescription opioids to manage chronic pain conditions



Elderly have increased risk of opioid toxicity due to alterations in PK and PD



Opioids have limited efficacy and utility for the long-term treatment of chronic pain



Elderly are at risk for opioid abuse and misuse and should be screened with monitoring and intervention, where indicated

# ACKNOWLEDGEMENTS

- Elena Balasanova, MD and Al Fisher, MD
- This program is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling \$751,695.00 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit [www.HRSA.gov](http://www.HRSA.gov).

**QUESTIONS**

